The U.S. Food and Drug Administration (FDA) has ordered new safety warnings for popular weight-loss and diabetes medications, including Ozempic, Wegovy, Mounjaro and Zepbound, over a rare eye condition that could cause permanent vision loss.
The warning, announced Monday, November 9, applies to all GLP-1 medications and concerns a condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which occurs when blood flow to the optic nerve is reduced.
According to the FDA, an analysis of 126 clinical trials involving more than 134,000 patients found approximately 6.4 cases per 100,000 patient-years among GLP-1 users, compared with 3.8 cases among patients receiving other treatments or a placebo.
Symptoms include sudden, painless vision loss, blurred vision, blind spots and distorted colours.
While the condition remains rare and a direct causal link has not been established, health officials are urging patients experiencing sudden vision changes to seek immediate medical attention.
The FDA says the updated warnings are intended to ensure patients and healthcare providers are better informed about the potential risks.







